SHPH · XBRL financial data

Shuttle Pharmaceuticals Holdings financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (SHPH's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q1 FY24Aug 13, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	433*	586	646	—	1,401	986*	1,574	1,026	943	512*	267	56
General and administrative	595*	325	310	—	329	429*	597	2,346	886	1,844*	1,161	1,985
Total operating expenses	1,283*	1,385	1,483	—	3,052	1,777*	2,951	3,910	2,267	2,788*	2,217	3,950
Operating income (loss)	(1,283)*	(1,385)	(1,483)	—	(3,052)	(1,777)*	(2,951)	(3,910)	(2,267)	(2,788)*	(2,217)	(3,950)
Interest income	22*	21	14	—	3	0*	—	0	0	1*	0	0
Interest expense	573*	446	387	—	—	—	—	—	—	—	—	—
Net income (loss)	(1,641)*	(1,731)	(2,031)	—	(3,784)	(1,598)*	(3,053)	(3,706)	(2,347)	(2,615)*	(2,152)	(3,146)
Earnings per share, basic USD per share	—	(0.10)	(0.96)	—	(1.59)	—	(0.30)	(3.29)	(1.05)	—	(0.43)	(3.10)
Earnings per share, diluted USD per share	—	(0.10)	(0.96)	—	(1.59)	—	(0.30)	(3.29)	(1.05)	—	(0.43)	(3.10)
Weighted average shares, basic thousands of shares	—	16,573	2,105	—	2,384	—	10,049	1,126	2,234	—	5,032	1,015
Weighted average shares, diluted thousands of shares	—	16,573	2,105	—	2,384	—	10,049	1,126	2,234	—	5,032	1,015

† Share count changed about 1/10 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (SHPH's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q1 FY24Aug 13, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	2,576	1,399	696	—	157	1,920	4,513	4,818	2,095	334	1,090	90
Marketable securities	2,887	2,789	1,643	—	—	—	—	—	—	—	—	—
Prepaid and other current assets	—	—	—	—	—	291	—	—	1,171	169	1,373	306
Total current assets	5,593	4,411	2,485	—	361	2,211	4,959	5,192	3,266	503	2,463	396
Property and equipment, net	25	23	22	—	21	19	18	19	18	17	16	15
Right-of-use asset	334	320	306	—	291	276	261	245	228	102	85	67
Total assets	5,952	4,754	2,813	—	674	2,506	5,310	5,504	3,543	10,476	11,809	22,811
Total current liabilities	1,042	1,489	1,385	—	1,659	1,534	1,782	1,693	1,965	7,967	8,306	3,481
Total deposits	6	—	—	—	—	—	—	—	—	—	—	—
Lease liability, non-current	304	289	267	—	256	238	220	195	175	155	134	112
Total liabilities	1,896	1,992	2,012	—	1,989	1,797	2,025	1,899	2,149	8,222	8,463	3,629
Accumulated deficit	(25,433)	(17,219)	(29,196)	—	(32,980)	(34,578)	(37,631)	(41,338)	(43,685)	(46,300)	(48,452)	(51,598)
Total stockholders' equity	4,056	2,761	801	—	(1,315)	709	3,285	3,606	1,394	2,254	3,346	19,182
Total liabilities and equity	5,952	4,754	2,813	—	674	2,506	5,310	5,504	3,543	10,476	11,809	22,811
Common shares outstanding (cover page) thousands of shares	16,795	16,795	2,227	2,227	3,665	4,077	10,984	1,071	1,603	5,591	5,851	4,765

† Share count changed about 1/10 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (SHPH's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q1 FY24Aug 13, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(1,641)*	(1,731)	(2,031)	—	(3,784)	(1,598)*	(3,053)	(3,706)	(2,347)	(2,615)*	(2,152)	(3,146)
Stock-based compensation	87*	111	71*	—	45*	32*	537	47*	134*	215*	35	(8)*
Net cash from operating activities	(1,062)*	(1,239)	(1,399)*	—	(1,999)*	(2,690)*	(2,527)	(3,355)*	(2,627)*	(973)*	(2,417)	(568)*
Purchases of property and equipment	0*	—	—	—	—	—	—	—	—	—	—	—
Net cash from investing activities	87*	101	1,158*	—	1,656*	0*	—	—	—	year only	(36)	(5,433)*
Proceeds from issuing common stock	—	—	—	—	—	year only	5,410	0*	0*	—	3,225	0*
Proceeds from long-term debt	—	600	—	—	—	—	—	—	—	—	—	—
Repayments of long-term debt	—	—	—	—	—	year only	—	—	—	—	—	—
Net cash from financing activities	(334)*	(40)	(462)*	—	(197)*	4,454*	5,119	3,660*	(96)*	2,269*	3,209	5,001*
Net change in cash	(1,310)*	(1,178)	(703)*	—	(539)*	1,763*	2,592	305*	(2,723)*	(1,761)*	756	(1,000)*

† Share count changed about 1/10 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Shuttle Pharmaceuticals Holdings	90	not reported	(568)*	4.8M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Aspira Women's Health	477	17	(2,010)*	46.6M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Creative Medical Technology Holdings	8,714	0	(1,472)*	6.6M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Target Group	14	1,381	(223)*	617.0M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Soligenix	9,811	not reported	(1,707)*	21.8M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Viskase Holdings	7,747	95,279	454*	14.3M	—	Q3 FY26 10-QSep 30, 2026
Matinas BioPharma Holdings	761	not reported	(1,836)*	14.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Xenetic Biosciences	6,472	661	(875)*	2.3M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Synlogic	13,183	0	(922)*	12.2M	14.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.